Martin Gleave

Dr. Martin Gleave is a Canadian surgeon and cancer researcher who was appointed to the Order of Canada in 2018.[1]

Gleave is a co-founder and Executive Director of the Vancouver Prostate Centre as well as a head of a department at University of British Columbia.

Gleave's team was recognized in 2010 as the first in the world to develop an anti-clusterin agent.[2]

Awards
  • Richard D. Williams MD Prostate Cancer Research Excellence Award[3]
  • Eugene Fuller Triennial Prostate Award from the American Urological Association[3]
  • Barringer Medal from the American Association of Genitourinary Surgeons[3]
  • BC Biotech Innovation and Achievement Award[3]
  • BC Innovation Council Frontiers in Research Award[3]
  • 2013 Aubrey J. Tingle Prize from Michael Smith Foundation for Health Research[4]

References
  1. Li, Wanyee (January 4, 2018). "B.C. doctor inducted into Order of Canada for innovative cancer treatments". Metro News Vancouver. Retrieved January 10, 2018.
  2. Crawford, Tiffany (August 28, 2010). "New cancer drug will prolong lives, Vancouver scientists say". Vancouver Sun. Retrieved 9 January 2018.
  3. "DR. MARTIN GLEAVE APPOINTED TO THE ORDER OF CANADA". Vancouver Coastal Health Research Institute. Retrieved January 9, 2018.
  4. "AJT Prize Recognizes Made-In-BC Advances In Prostate Cancer Treatment". msfhr.org. Retrieved January 9, 2018.


This article is issued from Wikipedia. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.